Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI

dc.contributor.buuauthorSağ, Salim
dc.contributor.buuauthorYıldız, Abdülmecit
dc.contributor.buuauthorAydın, Kaderli Aysel
dc.contributor.buuauthorGül, Bülent Cuma
dc.contributor.buuauthorBedir, Ömer
dc.contributor.buuauthorCeǧilli, Ercan
dc.contributor.buuauthorÖzdemir, Bülent
dc.contributor.buuauthorCan, Fatma Ezgi
dc.contributor.buuauthorAydınlar, Ali
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-8974-8837tr_TR
dc.contributor.orcid0000-0001-8404-8252tr_TR
dc.contributor.orcid0000-0002-1953-7735tr_TR
dc.contributor.researcheridAAI-6632-2021tr_TR
dc.contributor.researcheridAAW-9185-2020tr_TR
dc.contributor.scopusid12140008100tr_TR
dc.contributor.scopusid57192158999tr_TR
dc.contributor.scopusid7801322152tr_TR
dc.contributor.scopusid57140207000tr_TR
dc.contributor.scopusid57191868066tr_TR
dc.contributor.scopusid57144621700tr_TR
dc.contributor.scopusid7004168959tr_TR
dc.contributor.scopusid56689608500tr_TR
dc.contributor.scopusid57192164890tr_TR
dc.date.accessioned2022-12-28T12:39:52Z
dc.date.available2022-12-28T12:39:52Z
dc.date.issued2016-05-18
dc.description.abstractBackground: Contrast induced nephropathy (CIN) has been proven to be a clinical condition related to adverse cardiovascular outcomes. In recent studies, the monocyte to high density lipoprotein ratio (MHR) has been-postulated as a novel parameter associated with adverse renal and cardiovascular outcomes. In this study we-investigated the association of MHR with CIN in-ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Methods: Consecutive STEMI patients treated with primary PCI were prospectively recruited. Subjects were categorized into two groups; as patients who developed CIN (CIN+) and patients who did not develop CIN (CIN-) during hospitalization. CIN was defined as either a 25% increase in serum creatinine from baseline or 44.20 mu mol/L increase in absolute value, within 72 h of intravenous contrast administration. Results: A total number of 209 patients were included in the study. Thirty-two patients developed CIN (15.3%). In the CIN (+) patients, monocytes were higher [1.02 (0.83-1.39) vs. 0.69 (0.53-0.90) 109/L, p < 0.01] and HDL cholesterol levels were lower [0.88 (0.78-1.01) vs. 0.98 (0.88-1.14) mmol/L, p < 0.01]. In addition, MHR was significantly higher in the CIN (+) group [1.16 (0.89-2.16) vs. 0.72 (0.53-0.95) 10(9)/mmol, p < 0.01]. In multivariate logistic regression analysis, MHR, Mehran score, AGEF score and CV/eGFR were independently correlated with CIN. Conclusions: Higher MHR levels may predict CIN development after primary PCI in STEMI patients.en_US
dc.identifier.citationSağ, S. vd. (2017). ''Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI''. Clinical Chemistry and Laboratory Medicine, 55(1), 132-138.en_US
dc.identifier.endpage138tr_TR
dc.identifier.issn1434-6621
dc.identifier.issue1tr_TR
dc.identifier.pubmed27331308tr_TR
dc.identifier.scopus2-s2.0-84998636412tr_TR
dc.identifier.startpage132tr_TR
dc.identifier.urihttps://doi.org/10.1515/cclm-2016-0005
dc.identifier.urihttps://www.degruyter.com/document/doi/10.1515/cclm-2016-0005/html
dc.identifier.uri1437-4331
dc.identifier.urihttp://hdl.handle.net/11452/30143
dc.identifier.volume55tr_TR
dc.identifier.wos000388930700023tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWalter de Gruyterde
dc.relation.journalClinical Chemistry and Laboratory Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMedical laboratory technologyen_US
dc.subjectContrast induced nephropathyen_US
dc.subjectHDL-cholesterolen_US
dc.subjectMonocyteen_US
dc.subjectPercutaneous coronary interventionen_US
dc.subjectAcute kidney injuryen_US
dc.subjectHigh-density-lipoproteinen_US
dc.subjectElevation myocardial-infarctionen_US
dc.subjectCreatinine clearance ratioen_US
dc.subjectPrimary angioplastyen_US
dc.subjectCardiovascular eventsen_US
dc.subjectN-acetylcysteineen_US
dc.subjectRenal-functionen_US
dc.subjectRisk scoreen_US
dc.subject.emtreeAcetylsalicylic aciden_US
dc.subject.emtreeClopidogrelen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeHeparinen_US
dc.subject.emtreeHigh density lipoprotein cholesterolen_US
dc.subject.emtreeIohexolen_US
dc.subject.emtreeContrast mediumen_US
dc.subject.emtreeHigh density lipoprotein cholesterolen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAGEF scoreen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeContrast induced nephropathyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCoronary angiographyen_US
dc.subject.emtreeCoronary stentingen_US
dc.subject.emtreeCorrelation analysisen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeEstimated glomerular filtration rateen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHospitalizationen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLoading drug doseen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMehran scoreen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMonocyteen_US
dc.subject.emtreeMultivariate logistic regression analysisen_US
dc.subject.emtreePercutaneous coronary interventionen_US
dc.subject.emtreePercutaneous transluminal angioplastyen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProspective studyen_US
dc.subject.emtreeScoring systemen_US
dc.subject.emtreeST segment elevation myocardial infarctionen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeChemically induceden_US
dc.subject.emtreeCytologyen_US
dc.subject.emtreeKidney diseasesen_US
dc.subject.emtreeMonocyteen_US
dc.subject.emtreeReceiver operating characteristicen_US
dc.subject.emtreeST elevation myocardial infarctionen_US
dc.subject.meshAgeden_US
dc.subject.meshCholesterol, HDLen_US
dc.subject.meshContrast mediaen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshKidney diseasesen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMonocytesen_US
dc.subject.meshPercutaneous coronary interventionen_US
dc.subject.meshROC curveen_US
dc.subject.meshST elevation myocardial infarctionen_US
dc.subject.scopusContrast Induced Nephropathy; Coronary Angiography; Kidney Diseasesen_US
dc.subject.wosMedical laboratory technologyen_US
dc.titleAssociation of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCIen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: